Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTURE
2024-519568-42-00Phase 2Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cancer comparing Avextra 10/10 arm with Placebo arm (2 arms). Primary endpoint: ESAS-TSDS total score at 8 weeks. Planned start Aug 2025; status: authorised.
02
Drugs
Avextra 10/10
03
Conditions
cancer
Beyond the preview
Go deeper on 2024-519568-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519568-42-00.